Provided by Tiger Trade Technology Pte. Ltd.

Takeda Pharmaceutical Co Ltd

18.26
-0.2000-1.08%
Post-market: 18.300.0400+0.22%16:24 EST
Volume:2.98M
Turnover:54.45M
Market Cap:57.69B
PE:81.25
High:18.38
Open:18.24
Low:18.20
Close:18.46
52wk High:18.50
52wk Low:12.99
Shares:3.16B
Float Shares:3.06B
Volume Ratio:1.21
T/O Rate:0.10%
Dividend:0.65
Dividend Rate:3.54%
EPS(TTM):0.2247
EPS(LYR):0.2245
ROE:1.50%
ROA:2.47%
PB:1.16
PE(LYR):81.34

Loading ...

Takeda Advances Phase 3 Teen Depression Trial, Underscoring Its Neuroscience Strategy

TIPRANKS
·
Feb 14

Takeda Pushes Pediatric Psoriasis Drug TAK-279 Forward With New Phase 3 Trial Update

TIPRANKS
·
Feb 14

Takeda Advances Oral Crohn’s Disease Drug TAK-279 With Active Mid-Stage Trial

TIPRANKS
·
Feb 12

Takeda granted Priority Review for oveporexton by FDA

TIPRANKS
·
Feb 10

Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery

Benzinga
·
Feb 10

Takeda Pharmaceutical Invests $1.7 Billion in Iambic to Expand AI-Powered Drug Discovery

Deep News
·
Feb 09

Takeda’s TAK-188 Trial: Early Immunotherapy Bet in Advanced Solid Tumors

TIPRANKS
·
Feb 07

Takeda Advances TAK-360 Sleep Disorder Trial, Signaling Growing Ambition in Orexin-Based Therapies

TIPRANKS
·
Feb 07

Takeda Advances TAK-279 in Ulcerative Colitis: What Investors Should Watch Next

TIPRANKS
·
Jan 31

Takeda Flags Vyvanse Hit, Lifts 2025 Profit Guidance On Cost Control

Benzinga
·
Jan 29

Takeda raises FY25 core EPS view to 486 yen from 479 yen

TIPRANKS
·
Jan 29

Takeda reports Q3 core EPS 428 yen vs. 443 yen last year

TIPRANKS
·
Jan 29

Takeda Pharmaceutical Q3 Adj. EPS $0.47 Misses $0.55 Estimate, Sales $7.600B Miss $8.530B Estimate

Benzinga
·
Jan 29

Press Release: Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE(R) Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead

Dow Jones
·
Jan 29

Medicare is about to start negotiating the prices of medications administered by doctors

Dow Jones
·
Jan 28

Takeda Expected to Report Sharply Higher Third-Quarter Net Profit -- Earnings Preview

Dow Jones
·
Jan 28

Takeda Advances TAK-861 Into Phase 3 for Narcolepsy With Cataplexy, Setting Up a New CNS Catalyst

TIPRANKS
·
Jan 24

Takeda's (TAK.US) New Class 1 Drug Oveporexton Tablets Recommended for Priority Review, Intended for Type 1 Narcolepsy Patients

Stock News
·
Jan 23

Takeda Pharmaceutical Launches Liquid Medicine for Primary Immunodeficiency in US

MT Newswires Live
·
Jan 22

Earning Preview: Takeda Pharmaceutical Co Ltd — this quarter’s revenue is expected to increase by 6.05%, and institutional views are constructive

Earnings Agent
·
Jan 22